Atherosclerotic vascular disorders in HIV infected patients

Artery Research

Volumn 5, Issue 3, 2011, Pages 81-90

  Palios, John ^a   Ikonomidis, Ignatios ^a   Lekakis, John ^a   Anastasiou Nana, Maria ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Arterial stiffness; Atherosclerosis; Carotid; HAART; HIV; Microcirculation

Indexed keywords

ATAZANAVIR; ATORVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; ROSUVASTATIN;

ARTERIAL STIFFNESS; ARTERY WALL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MEDICAL DOCUMENTATION; METABOLIC PARAMETERS; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; VIRUS LOAD;

EID: 80051945850     PISSN: 18729312     EISSN: 18764401     Source Type: Journal    
DOI: 10.1016/j.artres.2011.04.001     Document Type: Review

References (56)

1. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-861.
2. Guaraldi G., Stentarelli C., Zona S., Orlando G., Carli F., Ligabue G., et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 2010, 208:222-227.
3. Grinspoon S., Carr A. Cardiovascular risk and body fat abnormalities in HIV infected adults. New Engl J Med 2003, 349:48-62.
4. Friis-Moller N., Sabin C.A., Weber R., d'Arminio Monforte A., El-Sadr W.M., Reiss P., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003.
5. Charakida M., Donald A.E., Green H., Storry C., Clapson M., Caslake M., et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation 2005, 112:103-109.
6. Hsue P.Y., Hunt P.W., Wu Y., Schnell A., Ho J.E., Hatano H., et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009, 23:2021-2027.
7. Lekakis J., Tsiodras S., Ikonomidis I., Palios J., Poulakou G., Rallidis L., et al. HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease. Clin Sci 2008, 115:189-196.
8. Thomas C.M., Smart E.J. How HIV protease inhibitors promote atherosclerotic lesion formation. Curr Opin Lipidol 2007, 18:561-565.
9. Coll B., Parra S., Alonso-Villaverde C., Aragonés G., Montero M., Camps J., et al. The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection. Stroke 2007, 38(9):2477-2484.
10. Mondy K.E. Determinants of endothelial function in human immunodeficiency virus infection: a complex interplay among therapy, disease, and host factors. J Cardiometab Syndr 2008, 3(2):88-92.
11. Kaplan R.C., Kingsley L.A., Gange S.J., Benning L., Jacobson L.P., Lazar J., et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008, 22(13):1615-1624.
12. Francisci D., Giannini S., Baldelli F., Leone M., Belfiori B., Guglielmini G., et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009, 23(5):589-596.
13. Hsue P.Y., Hunt P.W., Schnell A., Kalapus S.C., Hoh R., Ganz P., et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009, 23(9):1059-1067.
14. Dressman J., Kincer J., Matveev S.V., Guo L., Greenberg R.N., Guerin T., et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD-36 dependent cholesterol accumulation in macrophages. J Clin Invest 2003, 111:389-397.
15. Zangerle R., Sarcletti M., Gallati H., Reibnegger G., Wachter H., Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr 1994, 7(11):1149-1156.
16. Zangerle R., Fuchs D. Increased cardiovascular risk in patients with human immunodeficiency virus infection under highly active antiretroviral therapy. Am J Cardiol 2008, 102(3):373-374.
17. Hoffmann G., Kenn S., Wirleitner B., Deetjen C., Frede S., Smolny M., et al. Neopterin induces nitric oxide-dependent apoptosis in rat vascular smooth muscle cells. Immunobiology 1998, 199:63-73.
18. Eugenin E.A., Morgello S., Klotman M.E. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol 2008, 172:1100-1111.
19. Palios J., Ikonomidis I., Lekakis J., Tsiodras S., Poulakou G., Antoniadou A., et al. Microcirculatory vascular dysfunction in HIV-1 infected patients receiving highly active antiretroviral therapy. Microcirculation 2010, 17:303-310.
20. Kingsley L.A., Cuervo-Rojas J., Muñoz A., Palella F.J., Post W., Witt M.D., et al. Subclinical coronary atherosclerosis, HIV infection and antiretroviral therapy: multicenter AIDS Cohort Study. AIDS 2008, 22(13):1589-1599.
21. Mildvan D., Spritzler J., Grossberg S.E., Fahey J.L., Johnston D.M., Schock B.R., et al. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV -1 infection. Clin Infect Dis 2005, 40(6):853-858.
22. Zangerle R., Widner B., Quirchmair G., Neurauter G., Sarcletti M., Fuchs D. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV -1 infection. Clin Immunol 2002, 104:242-247.
23. Lichtner M., Cuomo M.R., Rossi R., Strano S., Massetti A.P., Mastroianni C.M., et al. Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment. Atherosclerosis 2009, 204(2):e1-e3.
24. Guaraldi G., Zona S., Alexopoulos N., Orlando G., Carli F., Ligabue G., et al. Coronary aging in HIV-infected patients. Clin Infect Dis 2009, 49:1756-1762.
25. Maggi P., Perilli F., Lillo A., Carito V., Epifani G., Bellacosa C., et al. An ultra sound based comparative study on carotid plaques in HIV-positive patients vs. atherosclerotic and arteritis patients: atherosclerotic or inflammatory lesions?. Coron Artery Dis 2007, 1:23-29.
26. Maggi P., Volpe A., Bellacosa C., Pastore G., Perilli F., Lillo A., et al. The role of immune reconstitution in the onset of subclinical atheromasic lesions. J Acquir Immune Defic Syndr 2009, 52(4):524-525.
27. Hulten E., Mitchell J., Scally J., Gibbs B., Villines T.C. HIV positivity, protease inhibitor exposure, and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart 2009, 95:1826-1835.
28. Lekakis J.P., Papamichael C.M., Cimponeriu A.T., Stamatelopoulos K.S., Papaioannou T.G., Kanakakis J., et al. Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis. Am J Cardiol 2000, 85:949-952.
29. Chambless L.E., Heiss G., Folsom A.R. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997, 146:483-494.
30. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., Wolfson S.K. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999, 340:14-22.
31. Laurent S., Boutouyrie P., Asmar R., Gautier I., Laloux B., Guize L., et al. Aortic stiffness is an independent predictor of all cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37:1236-1241.
32. Lekakis J., Ikonomidis I., Palios J., Tsiodras S., Karatzis E., Poulakou G., et al. Association of highly active antiretroviral therapy with increased arterial stiffness in patients infected with human immunodeficiency virus. Am J Hypertens 2009, 22(8):828-834.
33. Schillaci G., De Socio G.V., Pirro M., Savarese G., Mannarino M.R., Baldelli F., et al. Impact of treatment with protease inhibitors on aortic stiffness in patients with HIV infection. Arterioscer Thromb Vasc Biol 2005, 25:2381-2385.
34. Schillaci G., De Socio G.V., Pucci G., Mannarino M.R., Helou J., Pirro M., et al. Aortic stiffness in untreated adult patients with human immunodeficiency virus infection. Hypertension 2008, 52:308-313.
35. Sevastianova K., Sutinen J., Westerbacka J., Ristola M., Yki-Jarvinen H. Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy. Antivir Ther 2005, 10(8):925-935.
36. van Vonderen M.G., Smulders Y.M., Stehouwer C.D., Danner S.A., Gundy C.M., Vos F., et al. Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr 2009, 50(2):153-161.
37. Vlachopoulos C., Sambatakou H., Tsiachris D., Mariolis I., Aznaouridis A., Ioakeimidis N., et al. Impact of human immunodeficiency virus infection on arterial stiffness and wave reflections in the early disease stages. Top of Form. Artery Research 2009, 3(3):104-110.
38. Neunteufl T., Heher S., Katzenschlager R. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am. J Cardiol 2000, 86:207-210.
39. Gokce N., Keaney J.F., Hunter L.M., Watkins M.T., Vita J.A. Predictive value of non invasively determined endothelial dysfunction for long-term crdiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003, 41:1769-1775.
40. Karatzis E.N., Ikonomidis I., Vamvakou G.D., Papaioannou T.G., Protogerou A.D., Andreadou I., et al. Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. Am J Cardiol 2006, 98:1424-1428.
41. Solages A., Vita J.A., Thornton D.J. Endothelial function in HIV-infected persons. Clin Infect Dis 2006, 42:1325-1332.
42. Jiang B., Hebert V.Y., Li Y., Mathis J.M., Alexander J.S., Dugas T.R. HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol Appl Pharmacol 2007, 224(1):60-71.
43. Flammer A.J., Vo N.T., Ledergerber B., Hermann F., Gämperli A., Huttner A., et al. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial. Heart 2009, 95(5):385-390.
44. Lorenz M.W., von Kegler S., Steinmetz H., Markus H.S., Sitzer M. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006, 37:87-92.
45. Giuliano Ide C., de Freitas S.F., de Souza M., Caramelli B. Subclinic atherosclerosis and cardiovascular risk factors in HIV-infected children: PERI study. Coron Artery Dis 2008, 19(3):167-172.
46. Lorenz M.W., Stephan C., Harmjanz A., Staszewski S., Bickel M., Sitzer M. Both long term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008, 196(2):720-726.
47. Jericó C., Knobel H., Calvo N., Sorli M.L., Guelar A., Gimeno-Bayón J.L., Saballs P., et al. Subclinical carotid atherosclerosis in HIVinfected patients. Role of combination antiretroviral therapy. Stroke 2006, 37:812-817.
48. Xiu Rui-Juan, Cheng Jun, Berglund O. Microcirculatory disturbances in AIDS patients. Microvasc Res 1991, 42:151-159.
49. Monsuez J.J., Dufaux J., Vittecoq D., Vicaut E. Reduced reactive hyperemia in HIV- infected patients. J Acquir Immune Defic Syndr 2000, 25:434-442.
50. Monsuez J.J., Charniot J.C., Escaut L., Teicher E., Wyplosz B., Couzigou C., et al. HIV-associated vascular diseases: structural and functional changes, clinical implications. Int J Cardiol 2009, 133(3):293-306.
51. Schuster I., Thöni G.J., Edérhy S., Walther G., Nottin S., Vinet A., et al. Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy. Am J Cardiol 2008, 101(8):1213-1217.
52. Lima E.M., Gualandro D.M., Yu P.C., Giuliano Ide C., Marques A.C., Calderaro D., et al. Cardiovascular prevention in HIV patients: results from a successful intervention program. Atherosclerosis 2009, 204(1):229-232.
53. De Lorenzo F., Boffito M., Collot-Teixeira S., Gazzard B., McGregor J.L., Shotliff K., et al. Prevention of atherosclerosis in patients living with HIV. Vasc Health Risk Manag 2009, 5(1):287-300.
54. Metroka C.E., Truong P., Gotto A.M. Treatment of HIV-associated dyslipidemia: a role for omega-3 fatty acids. AIDS Read 2007, 17(7):362-364.
55. Martinez E., Leyes P., Ros E. Effectiveness of lipid-lowering therapy in HIV patients. Curr Opin HIV AIDS 2008, 3(3):240-246.
56. Masiá M., Bernal E., Padilla S., García N., Escribano J.C., Martínez E., et al. A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk. J Antimicrob Chemother 2009, 64(3):589-598.